Lucid Diagnostics shares rise 13.55% after-hours after securing VA contract for EsoGuard esophageal cancer test.

Lucid Diagnostics surged 13.55% in after-hours trading following the announcement that its EsoGuard Esophageal DNA test was awarded a contract by the U.S. Department of Veterans Affairs. The test, now available within the VA healthcare system, targets patients with chronic heartburn at risk of esophageal cancer and is priced at the Medicare rate, ensuring scalability across 9 million veterans annually. This contract validates the product’s clinical utility and market potential, directly aligning with the stock’s upward movement. Other news, such as ownership structure and unrelated industry partnerships, did not sufficiently explain the magnitude of the price increase.